National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2025

PB 121 of 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following Determination.

Dated 21 October 2025    

Rebecca Richardson

Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Contents

1  Name...................................................1

2  Commencement............................................1

3  Authority................................................1

4  Schedules................................................1

Schedule 1—Amendments—General 2

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023 2

Schedule 2—Amendments—Additional designated brands effective from 1 April 2026              3

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023 3

1  Name

 (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2025.

 (2) This instrument may also be cited as PB 121 of 2025.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (table)

Omit:

2  Section 5 (table)

Omit:

3  Section 5 (table)

Omit:

4  Section 5 (table)

Omit:

5  Section 5 (table)

Omit:

6  Section 5 (table)

Omit:

7  Section 5 (table)

Omit:

Schedule 2—Amendments—Additional designated brands effective from 1 April 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (after table item dealing with the brand Cal-500 of the drug Calcium in the form Tablet, chewable, 500 mg (as carbonate))

Insert:

2  Section 5 (after table item dealing with the brand Rosuzet Composite Pack of the drug Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium))

Insert:

3  Section 5 (after table item dealing with the brand Ezetimibe/Atorvastatin GH 10/80 of the drug Ezetimibe with atorvastatin in the form Tablet 10 mg-80 mg)

Insert:

4  Section 5 (after table item dealing with the brand Flucil of the drug Flucloxacillin in the form Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL)

Insert:

5  Section 5 (after table item dealing with the brand Nitrolingual Pumpspray of the drug Glyceryl trinitrate in the form Sublingual spray (pump pack) 400 micrograms per dose, 200 doses)

Insert:

6  Section 5 (after table item dealing with the brand DBL Heparin Sodium of the drug Heparin in the form Injection 5,000 units (as sodium) in 0.2 ml)

Insert:

7  Section 5 (after table item dealing with the brand Oxytrol of the drug Oxybutynin in the form Transdermal patches 36 mg, 8)

Insert:

8  Section 5 (after table item dealing with the brand Lyclear of the drug Permethrin in the form Cream 50 mg per g, 30 g)

Insert:

9  Section 5 (after table item dealing with the brand Phenoxymethylpenicillin-AFT of the drug Phenoxymethylpenicillin in the form Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL)

Insert:

10  Section 5 (after table item dealing with the brand Teglutik of the drug Riluzole in the form Oral suspension 50 mg per 10 mL, 300 mL)

Insert:

11  Section 5 (after table item dealing with the brand TENOFOVIR/EMTRICITABINE 300/200 ARX of the drug Tenofovir with emtricitabine in the form Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg)

Insert:

12  Section 5 (after table item dealing with the brand Timoptol of the drug Timolol in the form Eye drops 5 mg (as maleate) per mL, 5 mL)

Insert:

13  Section 5 (after table item dealing with the brand Valproate Winthrop EC 500 of the drug Valproic acid in the form Tablet (enteric coated) containing sodium valproate 500 mg)

Insert: